Literature DB >> 24818712

Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice.

Tiejun Zhao1, Yorifumi Satou, Masao Matsuoka.   

Abstract

Adult T-cell leukemia (ATL) is an aggressive T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATL cells possess a CD4+ CD25+ phenotype, similar to that of regulatory T cells (Tregs). Tax has been reported to play a crucial role in the leukemogenesis of HTLV-1. The HTLV-1 bZIP factor (HBZ), which is encoded by the minus strand of the viral genomic RNA, is expressed in all ATL cases and induces neoplastic and inflammatory disease in vivo. To test whether HBZ and Tax are both required for T cell malignancy, we generated HBZ/Tax double transgenic mice in which HBZ and Tax are expressed exclusively in CD4+ T cells. Survival was much reduced in HBZ/Tax double-transgenic mice compared with wild type littermates. Transgenic expression of HBZ and Tax induced skin lesions and T-cell lymphoma in mice, resembling diseases observed in HTLV-1 infected individuals. However, Tax single transgenic mice did not develop major health problems. In addition, memory CD4+ T cells and Foxp3+ Treg cells counts were increased in HBZ/Tax double transgenic mice, and their proliferation was enhanced. There was very little difference between HBZ single and HBZ/Tax double transgenic mice. Taken together, these results show that HBZ, in addition to Tax, plays a critical role in T-cell lymphoma arising from HTLV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24818712     DOI: 10.1007/s00705-014-2099-y

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

1.  Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Koichi Ohshima; Tadashi Matsumoto; Masao Matsuoka
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

2.  Foxp3-dependent transformation of human primary CD4+ T lymphocytes by the retroviral protein tax.

Authors:  Li Chen; Dan Liu; Yang Zhang; Huan Zhang; Hua Cheng
Journal:  Biochem Biophys Res Commun       Date:  2015-09-14       Impact factor: 3.575

3.  Animals Models of Human T Cell Leukemia Virus Type I Leukemogenesis.

Authors:  Stefan Niewiesk
Journal:  ILAR J       Date:  2016

Review 4.  From Immunodeficiency to Humanization: The Contribution of Mouse Models to Explore HTLV-1 Leukemogenesis.

Authors:  Eléonore Pérès; Eugénie Bagdassarian; Sébastien This; Julien Villaudy; Dominique Rigal; Louis Gazzolo; Madeleine Duc Dodon
Journal:  Viruses       Date:  2015-12-07       Impact factor: 5.048

5.  HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors.

Authors:  Haruka Kinosada; Jun-Ichirou Yasunaga; Kazuya Shimura; Paola Miyazato; Chiho Onishi; Tomonori Iyoda; Kayo Inaba; Masao Matsuoka
Journal:  PLoS Pathog       Date:  2017-01-03       Impact factor: 6.823

Review 6.  HTLV-1 bZIP factor: the key viral gene for pathogenesis.

Authors:  Masao Matsuoka; Jean-Michel Mesnard
Journal:  Retrovirology       Date:  2020-01-08       Impact factor: 4.602

Review 7.  Viruses and Bacteria Associated with Cancer: An Overview.

Authors:  Davide Zella; Robert C Gallo
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

Review 8.  The Role of HBZ in HTLV-1-Induced Oncogenesis.

Authors:  Tiejun Zhao
Journal:  Viruses       Date:  2016-02-02       Impact factor: 5.048

Review 9.  Molecular Studies of HTLV-1 Replication: An Update.

Authors:  Jessica L Martin; José O Maldonado; Joachim D Mueller; Wei Zhang; Louis M Mansky
Journal:  Viruses       Date:  2016-01-27       Impact factor: 5.048

Review 10.  Mouse Models That Enhanced Our Understanding of Adult T Cell Leukemia.

Authors:  Sara Moodad; Abdou Akkouche; Rita Hleihel; Nadine Darwiche; Marwan El-Sabban; Ali Bazarbachi; Hiba El Hajj
Journal:  Front Microbiol       Date:  2018-03-28       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.